Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Expects Thin Strips Technology To Drive OTC Cough/Cold Sales

This article was originally published in The Tan Sheet

Executive Summary

Novartis Consumer Health is gearing up to launch new cough/cold products using a Thin Strips dosage form this summer

You may also be interested in...



OTC Makers Target Children With Mucinex Mini Melts, Triaminic For Infants

Several OTC manufacturers are focusing on the adolescent and children's markets with product launches planned for the 2006-2007 cough/cold season

OTC Makers Target Children With Mucinex Mini Melts, Triaminic For Infants

Several OTC manufacturers are focusing on the adolescent and children's markets with product launches planned for the 2006-2007 cough/cold season

OTC Makers Target Children With Mucinex Mini Melts, Triaminic For Infants

Several OTC manufacturers are focusing on the adolescent and children's markets with product launches planned for the 2006-2007 cough/cold season

Related Content

Topics

UsernamePublicRestriction

Register

PS096752

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel